N. M. Raghavendra

发表

2,4-dihydroxy benzaldehyde derived Schiff bases as small molecule Hsp90 inhibitors: rational identification of a new anticancer lead.

M. Galigniana, Gisela I. Mazaira, S. Dutta Gupta, 2015, Bioorganic chemistry.

Conserved Water Molecule-dependent Docking Strategy and Atom-Based 3D QSAR Studies to Design Heat Shock Protein 90 Inhibitors

C. Subrahmanyam, N. L. Gowrishankar, N. M. Raghavendra, 2020 .

Discovery of N‐pyridoyl‐Δ2‐pyrazolines as Hsp90 inhibitors

N. M. Raghavendra, Sundeep Kadasi, Ravali Yerroju, 2019, Archiv der Pharmazie.

Rational Identification of Hsp90 Inhibitors as Anticancer Lead Molecules by Structure Based Drug Designing Approach.

M. Galigniana, Gisela I. Mazaira, C. Subrahmanyam, 2019, Anti-cancer agents in medicinal chemistry.

Molecular docking study, synthesis and biological evaluation of Mannich bases as Hsp90 inhibitors.

M. Galigniana, Gisela I. Mazaira, C. Subrahmanyam, 2015, International journal of biological macromolecules.

Trans ethosomal hybrid composites of naproxen-sulfapyridine in hydrogel carrier: anti-inflammatory response in complete Freund’s adjuvant induced arthritis rats

N. M. Raghavendra, Sajeev Kumar Babasahib, Roaddy Well Born, 2022, Artificial cells, nanomedicine, and biotechnology.

Antidiabetic and Antioxidant Activity of Rhynchosia

C. Subrahmanyam, N. M. Raghavendra, J. Mary, 2014 .

Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer

N. M. Raghavendra, Nahid Abbas, P. S. Dhiwar, 2022, Medicinal Chemistry Research.

Computational analysis of natural product B-Raf inhibitors.

N. M. Raghavendra, Tenzin Adon, Pujan Sasmal, 2022, Journal of molecular graphics & modelling.

Evaluation of the polyherbal extract for antioxidant, anticancer and antidiabetic activity

N. M. Raghavendra, Divya Pingili, S. Anarthe, 2012 .

In Vitro Antioxidant and Antidiabetic activity of Asystasia gangetica (Chinese Violet) Linn. (Acanthaceae)

N. M. Raghavendra, S. Anarthe, N. Reddy, 2010 .

Natural heat shock protein 90 inhibitors in cancer and inflammation.

N. M. Raghavendra, Thadeu E M M Costa, C. Penido, 2020, European journal of medicinal chemistry.

Synthesis, pharmacological evaluation and docking studies of N-(benzo[d]thiazol-2-yl)-2-(piperazin-1-yl)acetamide analogs as COX-2 inhibitors.

C. Subrahmanyam, N. M. Raghavendra, A. Jyothsna, 2012, Bioorganic & medicinal chemistry letters.

Synthesis and Antimicrobial Activity of Some Novel Substituted Piperazinyl-quinazolin-3(4H)-ones

N. M. Raghavendra, P. M. Gurubasavarajaswamy, P. Thampi, 2008 .

Eco-sustainable synthesis and biological evaluation of 2-phenyl 1,3-benzodioxole derivatives as anticancer, DNA binding and antibacterial agents

N. M. Raghavendra, Sayanti Gupta, Swapna Aleti, 2016 .

Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru(II) complexes.

E. Barreiro, D. A. Rodrigues, N. M. Raghavendra, 2016, International journal of biological macromolecules.

Molecular docking study, synthesis and biological evaluation of Schiff bases as Hsp90 inhibitors.

M. Galigniana, Gisela I. Mazaira, S. Dutta Gupta, 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Isolation and characterization of triterpenoids from bark of Syzygium alternifolium (Wight) Walp

N. M. Raghavendra, A. Priyanka, N. V. L. Suvarchala, 2012 .

Dual or multi-targeting inhibitors: The next generation anticancer agents.

N. M. Raghavendra, Sundeep Kadasi, Divya Pingili, 2018, European journal of medicinal chemistry.

Protective effect of gedunin on TLR‐mediated inflammation by modulation of inflammasome activation and cytokine production: Evidence of a multitarget compound

P. Pacheco, N. M. Raghavendra, J. Temerozo, 2017, Pharmacological research.

Discoidin domain receptor inhibitors as anticancer agents: A systematic review on recent development of DDRs inhibitors, their resistance and structure activity relationship.

N. M. Raghavendra, Rohit Pal, P. S. Dhiwar, 2022, Bioorganic chemistry.

Computer aided discovery of potential anti-inflammatory (S)-naproxen analogs as COX-2 inhibitors.

N. M. Raghavendra, P. Divya, K. Ramakrishna, 2013, Medicinal chemistry (Shariqah (United Arab Emirates)).

Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications

N. M. Raghavendra, B. R. P. Kumar, S. Mandal, 2022, Molecular Diversity.

Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis

N. M. Raghavendra, B. Sajeev Kumar, Sujit Nayek, 2020 .

Synthesis of Novel 1,3-Diacetoxy-Acridones as Cytotoxic Agents and their DNA-Binding Studies

N. M. Raghavendra, Y. C. Mayur, N. Sathish, 2009 .

Mechanistic insights into the beneficial effects of curcumin on insulin resistance: opportunities and challenges.

Noohu Abdulla Khan, N. M. Raghavendra, P. Balakumar, 2023, Drug discovery today.

An updated literature on BRAF inhibitors (2018–2023)

N. M. Raghavendra, Rohit Pal, Abhishek Ghara, 2023, Molecular diversity.

Discovery of Novel 1,2,4‐Oxadiazolyl Triazole Hybrids as B‐Raf Inhibitors for the Treatment of Melanoma

N. M. Raghavendra, Divya Pingili, Prasad Svum, 2022, ChemistrySelect.

Design and Development of Novel Glitazones for Activation of PGC-1α Signaling Via PPAR-γ Agonism: A Promising Therapeutic Approach against Parkinson’s Disease

N. M. Raghavendra, S. Chidambaram, Sunanda Tuladhar, 2023, ACS omega.

Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration

P. Krishnan, N. M. Raghavendra, Narasimha M. Beeraka, 2021, Current Neuropharmacology.